SIRT6/NRF2/GPX4 signaling pathway

Overview

The SIRT6/NRF2/GPX4 signaling pathway is a three-tier cascade coordinating antioxidant defense and suppression of ferroptosis. SIRT6 is an NAD⁺-dependent deacetylase acting on chromatin — principally at H3K9 and H3K56 — which makes its activity a function of cellular NAD⁺ and therefore of metabolic state; it acts upstream to promote activity of the transcription factor NRF2 (nuclear factor erythroid 2-related factor 2). NRF2 is otherwise held down by kelch like ECH associated protein 1 (KEAP1), which targets it for continuous degradation; relieving that repression allows NRF2 to accumulate in the nucleus and transcribe cytoprotective genes, among them GPX4 (glutathione peroxidase 4), the selenoenzyme that reduces lipid peroxides and is the principal brake on ferroptotic death.

The output is protection against lipid peroxidation and oxidative stress: raising GPX4 reduces accumulation of lipid reactive oxygen species and the ferroptotic death that follows. It does not by itself lower Fe²⁺, which is set by separate iron-handling systems — ferritin storage, ferritinophagy and transporter-mediated import and export — so the axis limits the consequences of labile iron rather than the iron itself.

Its relevance is greatest where ferroptosis and oxidative stress drive pathology: type 2 diabetes-induced endothelial dysfunction, ischemic injury, heart failure and cancer therapy resistance. Interventions reported to engage it include folic acid, berberine, ergothioneine and selenium nanoparticles — the last acting on the limiting element of GPX4 itself, since a selenoenzyme cannot be made without selenium. As with other NRF2-centered axes, the therapeutic direction is context-dependent: reinforcement protects normal tissue under oxidative insult, while the same activity in a tumor sustains resistance to treatments intended to kill it.

Recent Publications Summary

Recent studies have linked the SIRT6/NRF2/GPX4 signaling pathway to protection against ferroptosis-associated tissue injury, particularly in diabetic vascular disease. In a T2DM model, folic acid alleviated endothelial cell injury and ferroptosis by upregulating the SIRT6/NRF2 pathway, reducing oxidative stress, Fe2+ accumulation, and lipid peroxidation; inhibition of SIRT6 reversed the protective effect in vitro 41906715Mar. This work positions SIRT6/NRF2/GPX4-related antioxidant signaling as a mechanistic node in diabetic endothelial dysfunction.

The pathway has also been implicated in broader antioxidant and anti-ferroptotic responses in nonvascular tissues. In UVB-induced skin photodamage, a ROS-responsive hydrogel delivering biogenic selenium nanoparticles improved skin lesions, reduced epidermal hyperplasia, and suppressed collagen degradation, with the therapeutic effect attributed in part to activation of GPx4/Nrf2 signaling and attenuation of ferroptosis 41983715Apr. Similarly, in diabetic wound repair, a body temperature-responsive Janus patch accelerated wound closure, enhanced collagen deposition, and reduced oxidative stress, with transcriptomic and protein analyses indicating involvement of antioxidant and ferroptosis-related pathways 42114775May.

Several recent cancer studies further underscore GPX4 as a key ferroptosis regulator within this signaling axis. In lung adenocarcinoma, inhibition of DLX6 sensitized cells to cisplatin by inducing GPX4-dependent ferroptosis, while in tyrosine kinase inhibitor-resistant Cancers, USP20 promoted resistance by deubiquitinating GPX4 and preserving its anti-ferroptotic function 42455236Jul41844497Mar. In triple-negative breast cancer, dual metabolic reprogramming strategies were developed to overcome GPX4-centered ferroptosis resistance, and in a tumor-homing liposomal system, metformin contributed to ferroptosis induction by suppressing SLC7A11-mediated glutathione synthesis and disabling GPX4-mediated lipid peroxide detoxification 41780429Mar41534499Jan.

Additional publications support the broader relevance of NRF2-centered antioxidant signaling in disease models studied alongside this pathway. Ergothioneine protected against ischemic stroke through PI3K/Akt/Nrf2 activation, berberine-metformin combination therapy improved diabetic encephalopathy via AMPK-Nrf2 modulation, and inhalable nanodelivery systems for pulmonary fibrosis reduced reactive oxygen species through Nrf2 pathway activation 42214028May42390621Jul41992617Apr. Together, these reports suggest that SIRT6/NRF2/GPX4-associated signaling is being explored as a therapeutic axis for limiting oxidative stress and ferroptosis across metabolic, inflammatory, and malignant diseases 41906715Mar41983715Apr42455236Jul41844497Mar.

What Changes, What Holds

1. SIRT6-linked protection now has direct support in diabetic endothelial injury
REINFORCES Folic acid’s benefit in T2DM endothelial injury fits the established view that SIRT6/NRF2/GPX4 signaling suppresses oxidative stress and ferroptosis. What is added is a more specific mechanistic placement of SIRT6 upstream in this disease setting, with loss of SIRT6 blunting protection 41906715Mar. That strengthens the pathway’s relevance to diabetic vascular dysfunction, but it does not displace the baseline mechanism or broaden it beyond the same antioxidant, anti-ferroptotic logic.

2. NRF2/GPX4 signaling is being extended into skin and wound repair, not redefined
REINFORCES The skin photodamage and diabetic wound findings stay within the baseline’s protective framework: NRF2/GPX4-associated antioxidant activity and ferroptosis suppression are again linked to tissue preservation and repair 41983715Apr42114775May. These studies broaden the tissue map beyond the vascular and cardiac examples already known, but they do not challenge the core account that this axis limits lipid peroxidation, oxidative stress, and ferroptotic injury.

3. GPX4 remains the central ferroptosis bottleneck in cancer resistance
REINFORCES Recent cancer work sharpens, rather than revises, the baseline claim that GPX4 is a primary ferroptosis defender and a therapeutic resistance node 42455236Jul41844497Mar. The new studies reinforce that disabling GPX4-dependent protection can restore drug sensitivity, while preserving GPX4 supports resistance. That makes the axis more clinically salient in oncology, but it does not contradict the established role of GPX4 in detoxifying lipid peroxides.

4. NRF2-centered antioxidant signaling is being used as a broader therapeutic readout
NEW DIRECTION These reports move beyond the specific SIRT6/NRF2/GPX4 cascade by showing NRF2 activation in stroke, diabetic encephalopathy, and pulmonary fibrosis models 42214028May42390621Jul41992617Apr. The baseline already covers NRF2 as an antioxidant regulator, but it does not name these disease roles. So the new work expands the pathway’s disease neighborhood rather than altering the established mechanism; it suggests a wider therapeutic context, not a different biology.

Overview update candidates: SIRT6/NRF2 involvement in diabetic endothelial dysfunction; broader tissue applications in skin photodamage and wound repair; GPX4-centered ferroptosis resistance in cancer.